News Medivation in merger talks with Sanofi and others Sources say Pfizer and Celgene are also interested.
News BIND accepts Pfizer bid following bankruptcy Bid of $20 million may be enough to acquire all of BIND's assets.
News Pfizer cholesterol drug succeeds in two late stage trials Pfizer's bococizumab cholesterol drug has met primary endpoint in two phase 3 trials, part of a series of six late-stage studies.
News Shire buys rights to Pfizer gastrointestinal drug Shire has bought rights to PF-00547659 for an undisclosed sum.
News Pfizer's antibody drug trial misses key survival target in A... Inotuzumab ozogamicin missed one of two endpoints in trial.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.